Subcutaneous immunoglobulin — the future of CIDP treatment?

被引：0

作者：

Benjamin R. Wakerley

Nobuhiro Yuki

机构：

[1] Gloucestershire Royal Hospital,Benjamin R. Wakerley is at the Department of Neurology, UK; and at the Nuffield Department of Clinical Neurosciences

[2] Great Western Road,and at the Nuffield Department of Clinical Neurosciences

[3] Gloucester GL1 3NN,Nobuhiro Yuki is at the Department of Medicine

[4] University of Oxford,undefined

[5] John Radcliffe Hospital,undefined

[6] Headley Way,undefined

[7] OX3 9DU,undefined

[8] Oxford,undefined

[9] UK.,undefined

[10] University of Oxford,undefined

[11] John Radcliffe Hospital,undefined

[12] Headley Way,undefined

[13] OX3 9DU,undefined

[14] Oxford,undefined

[15] UK.,undefined

[16] Eda Memorial Hospital,undefined

[17] Azamino-minami 1-1-1,undefined

[18] Aoba-ku,undefined

[19] Yokohama,undefined

[20] Kanagawa,undefined

[21] 225-0012,undefined

[22] Japan.,undefined

来源：

Nature Reviews Neurology | 2018年 / 14卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Results from the PATH study indicate that subcutaneous immunoglobulin is efficacious and well tolerated for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP). This finding represents an important step in the management of patients with immunoglobulin-responsive CIDP, with considerable implications for the cost of treatment and, most importantly, for these patients' quality of life.

引用

页码：130 / 131

页数：1

共 50 条

[1] Subcutaneous immunoglobulin - the future of CIDP treatment?
Wakerley, Benjamin R.
Yuki, Nobuhiro
NATURE REVIEWS NEUROLOGY, 2018, 14 (03) : 130 - 132
[2] , Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs
Markvardsen, Lars H.
Harbo, Thomas
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 378 : 19 - 25
[3] Practical application of subcutaneous immunoglobulin for maintenance treatment in CIDP: The PATH study
Dimachkie, Mazen
van Schaik, Ivo
Bril, Vera
van Geloven, Nan
Hartung, Hans-Peter
Lewis, Richard
Sobue, Gen
Lawo, John-Philip
Mielke, Orell
Durn, Billie
Cornblath, David
Merkies, Ingemar
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 (04) : 357 - 358
[4] SUBCUTANEOUS IMMUNOGLOBULIN IN CIDP: A TWO-YEAR EXPERIENCE
Topa, A.
Spina, E.
Iodice, R.
Tozza, S.
Ruggiero, L.
Dubbioso, R.
Esposito, M.
Santoro, L.
Manganelli, F.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 : S41 - S41
[5] SUBCUTANEOUS IMMUNOGLOBULIN IN CIDP: A TWO-YEAR EXPERIENCE
Topa, A.
Spina, E.
Iodice, R.
Tozza, S.
Ruggiero, L.
Dubbioso, R.
Esposito, M.
Santoro, L.
Manganelli, F.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2017, 22 (03) : 397 - 397
[6] Subcutaneous is better tolerate than intravenous immunoglobulin treatment: the experience with two CIDP patients
Pasini, E.
Liguori, R.
Avoni, P.
Donadio, V.
JOURNAL OF NEUROLOGY, 2014, 261 : S357 - S357
[7] SUBCUTANEOUS IMMUNOGLOBULIN IN CIDP: A 5 YEARS FOLLOW UP
Mazzeo, A.
Gentile, L.
Barcellona, C.
Vita, G.
Toscano, A.
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2018, 23 : S27 - S27
[8] Subcutaneous is better tolerated than intravenous immunoglobulin treatment: the experience with two CIDP patients
Pasini, E.
Liguori, R.
Avoni, P.
Donadio, V.
EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 544 - 544
[9] Nationwide randomized trial of two standardized regimen for tapering off subcutaneous immunoglobulin treatment in CIDP
Markvardsen, Lars
Sindrup, Soren
Holbech, Jakob
Christiansen, Ingelise
Andersen, Henning
JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2020, 25 (04) : 499 - 500
[10] Subcutaneous "bolus" immunoglobulin dose in CIDP: A proof-of concept study
Cocito, Dario
Peci, Erdita
Romagnolo, Alberto
Rigaldo, Simona
Rosso, Michela
Lopiano, Leonardo
Merola, Aristide
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 380 : 54 - 57

← 1 2 3 4 5 →